Identification of genetic risk factors associated with ischaemic stroke in young Mexican patients

Wendelboe, 2016, Global burden of thrombosis: epidemiologic aspects, Circ Res, 118, 1340, 10.1161/CIRCRESAHA.115.306841 Bang, 2015, Nontraditional risk factors for ischemic stroke: an update, Stroke, 46, 3571, 10.1161/STROKEAHA.115.010954 Putaala, 2009, Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry, Stroke, 40, 1195, 10.1161/STROKEAHA.108.529883 Ferro, 2010, Aetiological diagnosis of ischaemic stroke in young adults, Lancet Neurol, 9, 1085, 10.1016/S1474-4422(10)70251-9 Isordia-Salas, 2010, Factores genéticos del sistema hemostático en pacientes jóvenes con infarto agudo de miocardio, Cir Cir, 78, 93 Nesheim, 2005, The Discovery of TAFI, J Thromb Haemost, 3, 2139, 10.1111/j.1538-7836.2005.01280.x Brouwers, 2001, A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels, Blood, 98, 1992, 10.1182/blood.V98.6.1992 Schneider, 2002, Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme, J Biol Chem, 277, 1021, 10.1074/jbc.M104444200 Henry, 2001, Identification of polymorphisms in the promoter and the 3’ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled, Blood, 97, 2053, 10.1182/blood.V97.7.2053 Kohler, 2000, Plasminogen-activator inhibitor type 1 and coronary artery disease, N Engl J Med, 342, 1792, 10.1056/NEJM200006153422406 Sobel, 1999, Increased plasminogen activator inhibitor-1 and vasculopaty. A reconcilable paradox, Circulation, 99, 2496, 10.1161/01.CIR.99.19.2496 Gawaz, 1999, Evaluation of platelet membrane glycoproteins in coronary artery disease, Circulation, 99, E1, 10.1161/01.CIR.99.1.e1 Newman, 1989, The human platelet alloantigens, PLA1 and PLA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing, J Clin Invest, 83, 1778, 10.1172/JCI114082 Lloyd-Jones, 1996, The vascular biology of nitric oxide and its role in atherogenesis, Annu Rev Med, 47, 365, 10.1146/annurev.med.47.1.365 Marsden, 1993, Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene, J Biol Chem, 268, 17478, 10.1016/S0021-9258(19)85359-0 Naber, 2001, eNOS 894T allele and coronary blood flow at rest and during adenosine-induced hyperemia, Am J Physiol Heart Circ Physiol, 281, H1908, 10.1152/ajpheart.2001.281.5.H1908 Frosst, 1995, A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase, Nutr Genet, 10, 111, 10.1038/ng0595-111 Adams, 1993, Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial: TOAST: Trial of Org 10172 in Acute Stroke Treatment, Stroke, 24, 35, 10.1161/01.STR.24.1.35 Montaner, 2003, Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke, Stroke, 34, 1038, 10.1161/01.STR.0000063139.06585.45 Leebeek, 2005, High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke, J Thromb Haemost, 3, 2211, 10.1111/j.1538-7836.2005.01484.x Ladenvall, 2007, Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation, Arterioscler Thromb Vasc Biol, 27, 955, 10.1161/01.ATV.0000259354.93789.a6 de Bruijne, 2009, The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study, J Thromb Haemost, 7, 919, 10.1111/j.1538-7836.2009.03350.x Shi, 2014, Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis, Thromb Res, 134, 610, 10.1016/j.thromres.2014.06.023 Leebeek, 2005, High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke, J Thromb Haemost, 3, 2211, 10.1111/j.1538-7836.2005.01484.x Akatsu, 2004, TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction, Br J Haematol, 127, 440, 10.1111/j.1365-2141.2004.05219.x Kozian, 2010, Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study, Thromb Haemost, 103, 976, 10.1160/TH09-10-0682 You, 1997, Risk factors for stroke due to cerebral infarction in young adults, Stroke, 28, 1913, 10.1161/01.STR.28.10.1913 Aburto-Mejía, 2017, Hypofibrinolytic State in Subjects with Type 2 diabetes mellitus aggravated by the metabolic syndrome before clinical manifestations of atherothrombotic disease, Biomed Res Int, 2017, 6519704, 10.1155/2017/6519704 Tjärnlund-Wolf, 2012, Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases, Stroke, 43, 2833, 10.1161/STROKEAHA.111.622217 Bentley, 2010, Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants, PLoS ONE, 5, e9136, 10.1371/journal.pone.0009136 Ranellou, 2015, Polymorphisms in prothrombotic genes in young stroke patients in Greece: a case-controlled study, Blood Coagul Fibrinolysis, 26, 430, 10.1097/MBC.0000000000000274 Hu, 2017, Association between plasminogen activator inhibitor-1 genetic polymorphisms and stroke susceptibility, Mol Neurobiol, 54, 328, 10.1007/s12035-015-9549-8 Brouns, 2010, The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome, J Thromb Haemost, 8, 75, 10.1111/j.1538-7836.2009.03663.x Denome, 2016, Inhibition of thrombin-activable fibrinolysis inhibitor and plasminogen activator inhibitor-1 reduces ischemic brain damage in mice, Stroke, 47, 2419, 10.1161/STROKEAHA.116.014091 Van Goor, 2002, PLA1/A2 polymorphism of the platelet glycoprotein receptor IIb/IIIa in young patients with cryptogenic TIA or ischemic stroke, Thromb Res, 108, 63, 10.1016/S0049-3848(02)00356-0 Oksala, 2007, Smoking and the platelet fibrinogen receptor glycoprotein IIb/IIIA PlA1/A2 polymorphism interact in the risk of lacunar stroke and midterm survival, Stroke, 38, 50, 10.1161/01.STR.0000251719.59141.36 Pongrácz, 2007, The effects of platelet receptor GPIIb/IIIa polymorphism (Leu Pro33) on the receptor expression and platelet aggregation in patients with ischaemic stroke, Turk J Haematol, 24, 155 Kumar, 2016, Association between Endothelial nitric oxide synthase G894T gene polymorphism and risk of ischemic stroke in North Indian population: a case-control study, Neurol Res, 38, 575, 10.1080/01616412.2016.1181376 Kumar, 2017, Association between endothelial nitric oxide synthase gene polymorphisms and risk of ischemic stroke: a meta-analysis, Neurol India, 65, 22 Miao, 2014, Potential serum biomarkers in the pathophysiological processes of stroke, Expert Rev Neurother, 14, 173, 10.1586/14737175.2014.875471 Jiang, 2017, Methylenetetrahydrofolate reductase C677T polymorphism, hypertension and risk of stroke: a prospective, nested case-control study, Int J Neurosci, 127, 253, 10.1080/00207454.2016.1183126 Isordia-Salas, 2010, The C677T polymorphism of the methylenetetrahydrofolate reductase gene is associated with idiopathic ischemic stroke in the young Mexican-Mestizo population, Cerebrovasc Dis., 29, 454, 10.1159/000289349 Maasz, 2010, Three periods of one and a half decade of ischemic stroke susceptibility gene research: lessons we have learned, Genome Med., 2, 64, 10.1186/gm185